ESMO 2019: No Benefit for Sorafenib in Adjuvant Setting for Intermediate-to-High-Risk Renal Cell Carcinoma
SORCE trial shows that active surveillance remains the standard of care
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.